Gain Therapeutics (NASDAQ:GANX) vs. Larimar Therapeutics (NASDAQ:LRMR) Head-To-Head Comparison

Larimar Therapeutics (NASDAQ:LRMR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for Larimar Therapeutics and Gain Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1	0	8	1	2.90
Gain Therapeutics	1	0	6	0	2.71

Larimar Therapeutics currently has a consensus price target of $16.71, indicating a potential upside of 401.93%. Gain Therapeutics has a consensus price target of $8.67, indicating a potential upside of 275.18%. Given Larimar Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Larimar Therapeutics is more favorable than Gain Therapeutics.

Institutional and Insider Ownership

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Larimar Therapeutics and Gain Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$80.60 million	($1.93)	-1.73
Gain Therapeutics	$50,000.00	1,776.85	-$20.41 million	($0.61)	-3.79

Gain Therapeutics has higher revenue and earnings than Larimar Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Larimar Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.

Profitability

This table compares Larimar Therapeutics and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-91.83%	-74.60%
Gain Therapeutics	N/A	-341.32%	-174.09%

Summary

Larimar Therapeutics beats Gain Therapeutics on 9 of the 13 factors compared between the two stocks.

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.